Abstract: The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds.

Abstract: A strain sensor may have a conductive elastic yarn including a first fiber having a predetermined length and a shape of a fiber yarn and a second fiber having electrical conductivity and a sheet shape. The strain sensor may have a pair of wiring members electrically connected to both ends of the conductive elastic yarn. The conductive elastic yarn, with the second fiber wrapped around the first fiber, is twisted in a coil shape.

Abstract: The present invention relates to a switch molecule for activating a chimeric antigen receptor effector cell, to a polypeptide or fusion protein binding thereto, and to a chimeric antigen receptor. (i) When a switch molecule of the present invention is used, in order to improve safety of a CAR-T cell, if severe toxicity appears, a switch molecule lacking a targeting moiety can be injected to adjust activation of the CAR-T cell. (ii) When an antigen is mutated, or in order to cure various carcinomas, instead of an existing switch molecule, a switch molecule targeting a new antigen generated due to the mutation or a switch molecule targeting a different tumor associated antigen (TAA) can be injected into a patient to cure cancer more effectively.

Abstract: Provided is a fluorine-doped tin oxide support, a platinum catalyst for a fuel cell having the same, and a method for producing the same. Also described is a high electrical conductivity and electrochemical durability by doping fluorine to the tin oxide-based support through an electrospinning process. Thus, while resolving a degradation issue of the carbon support in the conventional commercially available platinum/carbon (Pt/C) catalyst, what is designed is to minimize an electrochemical elution of dopant or tin, which is a limitation of the tin oxide support itself and has excellent performance as a catalyst for a fuel cell.

Abstract: A molding method for a cover window includes: locally heating a peripheral portion of a glass substrate around a central portion of the glass substrate to a temperature of about 610° C. to about 670° C., forming a cover window by pressing the glass substrate, and annealing and cooling the cover window. Accordingly, a cover window in which each of edges has an outwardly convex curved surface through a glass substrate may be formed. In addition, the surface roughness of a cover window formed through a glass substrate may be improved.

Abstract: A logistics control system includes: a processor configured to control an operation of the logistics control system; and a memory storing instructions executable by the processor, wherein the processor is configured to execute the instructions to: obtain barcode information about an article from a barcode information obtaining module provided in the logistics control system and configured to obtain the barcode information attached to the article; obtain image information about the article from an image information obtaining module configured to obtain the image information about the article by synchronizing a photographing time point of the barcode information obtaining module with a photographing time point of the barcode information obtaining module; and monitor the article based on the barcode information and the image information.

Abstract: The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds.

Abstract: The present invention relates to: a novel antibody or an antigen-binding fragment thereof for use in the treatment of cancer by targeting B cell malignancies; a chimeric antigen receptor comprising the same; and uses thereof. The antibody of the present invention is an antibody specifically binding to CD19 highly expressed in cancer cells (particularly, blood cancer) and has very low homology compared to the CDR sequences of conventional CD19 target antibodies, and thus the sequence thereof is unique. In addition, cells expressing a chimeric antigen receptor comprising an anti-CD19 antibody or antigen-binding fragment of the present invention induce immune cell activity in response to a positive cell line expressing CD19, and thus can be usefully used as a therapeutic agent for CAR-immune cells.

Abstract: An exemplary embodiment of the present inventive concept provides a display device including: a display unit including a plurality of pixels disposed on a display area; a display controller configured to control the display unit; a sensor including a plurality of first sensing electrodes and a plurality of second sensing electrodes disposed in the display area; and a sensor controller configured to recognize a touch of a user inputted into the sensor in a touch sensing mode and to recognize a fingerprint of the user inputted into the sensor in a fingerprint sensing mode, wherein the sensor controller changes a mode to the fingerprint sensing mode when no touch is inputted for a predetermined time period in the touch sensing mode and changes the mode to the touch sensing mode when authorization on a fingerprint inputted into the sensor is succeeded in the fingerprint sensing mode.

Abstract: The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds.

Abstract: The present invention relates to a new antibody or an antigen binding fragment thereof for use in the treatment of cancer by targeting a B cell malignancy, a chimeric antigen receptor comprising the same, and a use of the same. The antibody of the present invention is an antibody for specifically binding to CD19 that is highly expressed in cancer cells (particularly, blood cancer), has very low homology to a CDR sequence thereof compared to a CDR sequence of a conventional CD19 target antibody so that the sequence thereof is unique, and specifically binds to an epitope that is different from a FMC63 antibody fragment binding to CD19 of the conventional art. A cell expressing the chimeric antigen receptor comprising an anti-CD19 antibody or the antigen binding fragment of the present invention induces immune cell activity in response to a positive cell line expressing CD19, and thus may be utilized as a CAR-immune cell therapeutic agent.

Abstract: A liquid crystal display (LCD) device includes an LCD panel with a number (N) of pixel elements for displaying an image. A dimming panel includes N dimming elements. The dimming panel has a first mode to apply a uniform dimming to the N dimming elements to provide a privacy function for the LCD device. The dimming panel further has a second mode to a apply a per-element dimming to provide a local dimming function for the LCD device.

Abstract: A liquid crystal display (LCD) device includes an LCD panel with a number (N) of pixel elements for displaying an image. A dimming panel includes N dimming elements. The dimming panel has a first mode to apply a uniform dimming to the N dimming elements to provide a privacy function for the LCD device. The dimming panel further has a second mode to a apply a per-element dimming to provide a local dimming function for the LCD device.

Abstract: The present invention relates to a new antibody or an antigen binding fragment thereof for use in the treatment of cancer by targeting a B cell malignancy, a chimeric antigen receptor comprising the same, and a use of the same. The antibody of the present invention is an antibody for specifically binding to CD19 that is highly expressed in cancer cells (particularly, blood cancer), has very low homology to a CDR sequence thereof compared to a CDR sequence of a conventional CD19 target antibody so that the sequence thereof is unique, and specifically binds to an epitope that is different from a FMC63 antibody fragment binding to CD19 of the conventional art. A cell expressing the chimeric antigen receptor comprising an anti-CD19 antibody or the antigen binding fragment of the present invention induces immune cell activity in response to a positive cell line expressing CD19.

Abstract: A portable information handling system integrates a display film having OLED pixels to a housing with a graphene foam having graphene particles disposed in an intermediary material with varied orientations that promote thermal transfer from the display film. For example, graphene particles disposed in a silicon resin to form the foam couples between a portable housing and a display film to transfer thermal energy to the portable housing from the display film.

Abstract: Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition. The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.

Abstract: Disclosed is a display module including a transparent display panel and a frame to fix a side of the transparent display panel, wherein the frame has a communication unit to receive data from the outside, a controller to process the received data and to output a drive command corresponding to the processed data and a display drive unit to drive the transparent display panel in response to the drive command from the controller. A display system includes a system body and a display module detachably mounted in the system body.

Abstract: An information handling system organic light emitting diode (OLED) display adapts presentation of visual information to manage a display thermal state, such as to maintain a uniform thermal condition. In one example embodiment, a first display zone of plural pixels presents visual images with a first refresh rate, such as the nominal refresh rate established by the display settings, and a second display zone presents visual images with a partial pixel refresh rate that reduces power dissipation and, thus, thermal energy release so that a more uniform thermal state may be achieved at the display.

Abstract: Disclosed herein are an anti-HER2 affibody and a switch molecule including a cotinine-conjugated anti-HER2 affibody. When applied in combination with Cot-sCART, the cotinine-conjugated anti-HER2 affibody reacts with HER2-positive cells to induce immune cell activity, thereby finding advantageous applications as switch molecules in sCART therapeutic agents.

Abstract: A display device unit includes: a display device; and a sound element disposed at a side surface or a rear surface of the display device, where the sound element includes a vibration material layer which provides a sound based on an electric field applied therein, and a pair of electrodes which generates the electric field in the vibration material layer.